AIMS: To further test whether the baclofen-induced suppression of motivation to consume alcohol in animals could be transposed to humans. METHODS: A patient who had neither tolerated nor benefited from other alcohol treatment modalities was put on trial with baclofen on a dosage up to 140 mg/day. RESULTS: The patient reported dramatic reduction in cravings for and preoccupation with alcohol. CONCLUSIONS: High-dose baclofen therapy was associated with complete and prolonged suppression of symptoms and consequences of alcohol-dependence.
AIMS: To further test whether the baclofen-induced suppression of motivation to consume alcohol in animals could be transposed to humans. METHODS: A patient who had neither tolerated nor benefited from other alcohol treatment modalities was put on trial with baclofen on a dosage up to 140 mg/day. RESULTS: The patient reported dramatic reduction in cravings for and preoccupation with alcohol. CONCLUSIONS: High-dose baclofen therapy was associated with complete and prolonged suppression of symptoms and consequences of alcohol-dependence.
Authors: Giovanni Addolorato; Lorenzo Leggio; F Woodward Hopf; Marco Diana; Antonello Bonci Journal: Neuropsychopharmacology Date: 2011-10-26 Impact factor: 7.853
Authors: Caroline D Rae; Joanne E Davidson; Anthony D Maher; Benjamin D Rowlands; Mohammed A Kashem; Fatima A Nasrallah; Sundari K Rallapalli; James M Cook; Vladimir J Balcar Journal: J Neurochem Date: 2013-12-18 Impact factor: 5.372
Authors: Klaus A Miczek; Joseph F DeBold; Lara S Hwa; Emily L Newman; Rosa M M de Almeida Journal: Ann N Y Acad Sci Date: 2015-08-18 Impact factor: 5.691
Authors: Teresa R Franklin; Derek Harper; Kyle Kampman; Susan Kildea-McCrea; Will Jens; Kevin G Lynch; Charles P O'Brien; Anna Rose Childress Journal: Drug Alcohol Depend Date: 2009-04-23 Impact factor: 4.492